News | December 25, 2025
Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
Subscribe To Our Newsletter & Stay Updated
